Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06458465
Status:
RECRUITING
Last Update Posted:
2024-06-13
First Post:
2024-05-24
Brief Title:
Impact of Curcumin and Pentoxiphylline on Chronic Kidney Disease Patients
Sponsor:
Alexandria University
Organization:
Alexandria University
Study Overview
Official Title:
Clinical Study Evaluating the Impact of Curcumin and Pentoxiphylline on Patients With Chronic Kidney Disease
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CKD
Brief Summary:
The aim of the study is to evaluate the impact of turmeric and pentoxiphylline on serum levels of protein-bound uremic toxin p-cresyl sulfate oxidative stress biomarker level Malonaldehyde inflammatory biomarker level Highly sensitive C-reactive protein In addition to the evaluation of its effect on metabolic profile and disease progression in chronic kidney disease patients
Detailed Description:
1 Ethical committee approval has been obtained from Ethics committee of Faculty of Medicine Alexandria University
2 All participants should agree to take part in this clinical study and will provide informed consent
3 Sixty chronic kidney disease patients will be recruited from the Kidney and Urology Center KUC and Alexandria main university hospital AMUH
The 60 participants will be randomly assigned into 3 arms
Group 1 Control group n20 Patients will be treated with standard care only for 6 months Group 2 n20 Patients will be treated with the same standard care plus curcumin capsules 500 mg twice daily for 6 months Group 3 n20 Patients will be treated with the same standard care plus pentoxiphylline 400 mg twice daily for 6 months
4 All patients will be submitted to
Full patient history and clinical examination Blood withdrawal in order to conduct lab work
5 Patients demographic data will be recorded with respect to age weight and other co-morbidities
6 Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results
7 Results conclusion discussion and recommendations will be given
2 All participants should agree to take part in this clinical study and will provide informed consent
3 Sixty chronic kidney disease patients will be recruited from the Kidney and Urology Center KUC and Alexandria main university hospital AMUH
The 60 participants will be randomly assigned into 3 arms
Group 1 Control group n20 Patients will be treated with standard care only for 6 months Group 2 n20 Patients will be treated with the same standard care plus curcumin capsules 500 mg twice daily for 6 months Group 3 n20 Patients will be treated with the same standard care plus pentoxiphylline 400 mg twice daily for 6 months
4 All patients will be submitted to
Full patient history and clinical examination Blood withdrawal in order to conduct lab work
5 Patients demographic data will be recorded with respect to age weight and other co-morbidities
6 Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results
7 Results conclusion discussion and recommendations will be given
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None